Vetter, one of the global leaders in the aseptic manufacturing of drug-delivery systems, servicing the top-ten pharma/biotech companies worldwide along with mid-size firms and emerging startups, today announced the opening of a new business entity in Tokyo, Japan.
Mr. Hiroaki Suzuki in his role as Business Development Manager for Vetter Pharma International Japan K.K., will lead Vetter’s business activities in Japan, reporting to Ms. Chervee Ho based in Singapore in her role as Director Key Account Management Asia Pacific.
The new office underlines the importance of Japan for Vetter’s business activities. As the second largest pharmaceutical single market, Japan is home to a number of leading global companies which offer a promising injectable pipeline. It is also a point of departure for several established Japanese companies for increasing their global reach. As such, the new office will support customer relations and aid in the development of new business within Japan, while strengthening the global position of Vetter, particularly in selected Asia Pacific markets. As a strategic partner, Vetter supports its worldwide clients through every phase of their drug product’s lifecycle, from early product development to launch to commercial supply.
“For more than 35 years, the name Vetter has been synonymous with high-quality aseptically prefilled drug-delivery systems. With our office opening in Japan, we continue to build upon that history with a further demonstration of our strategy to better service the needs of our growing customer base worldwide, including Asia,” said Udo J. Vetter, Chairman of the Advisory Board and member of the owner family.
The new office is located in district Shinagawa, which is one of the 23 wards of Tokyo, and a rapidly developing area. Situated on the 28th floor of a business tower directly across from Shinagawa station, being one of the transportation hubs in Tokyo, the office offers ease of accessibility for many JR Rail lines with proximity to international Haneda and Narita airport through direct train connections.
For more information, visit www.vetter-pharma.com